

Curriculum Vitae

Personal information



First name(s) / Surname(s) **Davide Giuseppe RIBALDONE**

Address(es) Via Principi d'Acaja 6, 10143, Torino, Italy

Telephone(s) Mobile:

E-mail

Nationality Italian

Date of birth 22/11/1983

Gender Male

Work experience

<p>Dates</p> <p>Occupation or position held</p> <p>Main activities and responsibilities</p>	<p>From December 2022 to today</p> <p>Associate professor, Consultant Gastroenterologist</p> <ul style="list-style-type: none"> • Research in collaboration with Italian and foreign centers of excellence (inflammatory bowel disease, microbiome) • Teaching • Outpatient activity in the regional high specialization centre for inflammatory bowel diseases, including management of biological drugs, small molecules, and biobank • Gastro-hepatology ward • Fecal microbiota transplant • Pharmacological trials
---	--

Name and address of employer **Università degli Studi di Torino – Department of Medical Sciences; A.O.U. "CITTÀ DELLA SALUTE E DELLA SCIENZA DI TORINO"**

<p>Dates</p> <p>Occupation or position held</p> <p>Main activities and responsibilities</p>	<p>From December 2019 to December 2022</p> <p>Assistant Professor, Consultant Gastroenterologist</p> <ul style="list-style-type: none"> • Research in collaboration with Italian and foreign centers of excellence (microbiome, inflammatory bowel disease) • Project of excellence of the Department of Medical Sciences (new markers in cardio-metabolic diseases) • Teaching • Outpatient activity in the regional reference center for inflammatory bowel diseases, including management of biological drugs and biobank • Gastro-hepatology ward • Pharmacological trials
---	---

Name and address of employer **Università degli Studi di Torino – Department of Medical Sciences; A.O.U. "CITTÀ DELLA SALUTE E DELLA SCIENZA DI TORINO"**

<p>Dates</p> <p>Occupation or position held</p> <p>Main activities and responsibilities</p>	<p>From October 2018 to July 2022</p> <p>PhD student</p> <ul style="list-style-type: none"> • Organic volatiles metabolites assessment in inflammatory bowel diseases • Numerous publications in collaboration with Italian and European centres of excellence • Organization of national and international scientific congresses
---	---

Name and address of employer	Università degli Studi di Torino – Department of Surgical Sciences
Dates	From August 2018 to September 2018
Occupation or position held	Fellow
Main activities and responsibilities	<ul style="list-style-type: none"> • IBD-BioBank • Numerous publications in collaboration with Italian and European centres of excellence • Outpatient Clinic, regional reference centre for inflammatory bowel diseases • Pharmacological trials
Name and address of employer	Università degli Studi di Torino – Department of Medical Sciences
Dates	From August 2017 to July 2018
Occupation or position held	Research Fellow
Main activities and responsibilities	<ul style="list-style-type: none"> • IBD-BioBank • Numerous publications in collaboration with Italian and European centres of excellence • Outpatient Clinic, regional reference centre for inflammatory bowel diseases • Digestive endoscopy (diagnostic and operative gastroscopy and colonoscopy) • Pharmacological trials
Name and address of employer	Università degli Studi di Torino – Department of Medical Sciences
Dates	From July 2012 to July 2017
Occupation or position held	Junior specialist physician, Gastroenterology
Main activities and responsibilities	<ul style="list-style-type: none"> • Digestive endoscopy (diagnostic and operative gastroscopy and colonoscopy, capsule endoscopy) • Division of Gastro-Hepatology, centre of excellence for liver disease • Outpatient Clinic, centre of excellence for inflammatory bowel diseases: biologic drugs, biobank • Outpatient Clinic, esophageal and gastric diseases • Outpatient liver transplant • Liver cancer diagnosis and therapy • Abdominal and bowel ultrasound • Day Hospital • Emergency Medicine (5 months)
Name and address of employer	A.O.U. "CITTÀ DELLA SALUTE E DELLA SCIENZA DI TORINO"
Dates	From March 2009 to July 2012
Occupation or position held	Attending physician
Main activities and responsibilities	<ul style="list-style-type: none"> • Assistance to structured physicians in the management of outpatient visits (center of excellence for inflammatory bowel diseases, gastric diseases, liver diseases) • Medical statistics and production of multiple publications in English
Name and address of employer	Department of Gastro-Hepatology, S. Giovanni Battista (Molinette) Hospital - SGAS, Via Cavour, n° 31
Dates	From May 2005 to June 2005
Occupation or position held	Trainee
Main activities and responsibilities	Design of a VoIP network for the region Piemonte
Name and address of employer	Netbrain Srl, Torino

Education and training

Dates	From October 2018 to July 2022
Title of qualification awarded	Doctoral degree in Bioengineering and Medical-Surgical Sciences
Name and type of organisation providing education and training	Università degli Studi di Torino and Politecnico di Torino
	Score: excellent
	Title of the thesis: INFLAMMATORY BOWEL DISEASES: NEW BIOLOGICAL DRUGS' INDICATION AND SURGICAL INDICATION
	Tutors: prof. MARIO MORINO and prof. ALBERTO AREZZO

Dates	From July 2012 to July 2017																														
Title of qualification awarded	Specialist in Gastroenterology																														
Name and type of organisation providing education and training	Università degli Studi di Torino																														
	Score: 70/70 cum laude, press dignity Title of the thesis: ANTI-TNF AND ANTI-TNF ANTIBODIES THROUGH LEVELS DOSAGE: IMPLEMENTATION AND CLINICAL USE IN THE INFLAMMATORY BOWEL DISEASES Thesis supervisor: prof. GIORGIO MARIA SARACCO																														
Dates	From September 2005 to July 2011																														
Title of qualification awarded	Licensed to Practice Medicine (M.D.)																														
Name and type of organisation providing education and training	Università degli Studi di Torino																														
	Score: 110/110 cum laude, press dignity Title of the thesis: BOWEL ULTRASOUND AS PREDICTOR OF CROHN'S DISEASE RECURRENCE AFTER RESECTION Thesis supervisor: prof. RIZZETTO MARIO <i>Dissertation awarded with the Honorable Mention conferred by the Academy of Medicine of Torino Winner for 4 consecutive years of scholarship for merit</i>																														
Dates	From September 2002 to September 2005																														
Title of qualification awarded	Bachelor, Telecommunication Engineering																														
Name and type of organisation providing education and training	Politecnico di Torino																														
	Score: 103/110 Title of the thesis: REALIZZAZIONE DI UNA RETE VoIP PER LA REGIONE PIEMONTE Thesis supervisor: prof. MUNAFO' MAURIZIO																														
Dates	From September 1997 to June 2002																														
Title of qualification awarded	Scientific high school degree																														
Name and type of organisation providing education and training	Liceo scientifico Faà di Bruno																														
	Score: 100/100																														
Other training activities	<ul style="list-style-type: none"> • Practical courses about bowel ultrasonography attended as a learner: 3 • Scientific meetings attended as listener: 86 • from September to December 2020 - Quality teaching in presence and at a distance, evaluation and inclusion – participant Issued by University of Turin • from September 2021 to May 2022 - Design, management and evaluation of teaching activities at universities – participants Issued by University of Turin • April 2018 March 2020 – GOOD CLINICAL PRACTICE courses • from May 2017 to June 2017 - Training Course on Health and Safety for Workers • from March 2007 to May 2007 - BLS - D/PBLS according to the guidelines ILCOR 2005 																														
Personal skills and competences																															
Mother tongue(s)	Italian																														
Other language(s)																															
Self-assessment																															
European level (*)																															
English	<table border="1"> <thead> <tr> <th colspan="4">Understanding</th> <th colspan="4">Speaking</th> <th colspan="2">Writing</th> </tr> <tr> <th colspan="2">Listening</th> <th colspan="2">Reading</th> <th colspan="2">Spoken interaction</th> <th colspan="2">Spoken production</th> <th colspan="2"></th> </tr> </thead> <tbody> <tr> <td>B1</td> <td>Independent user</td> <td>C2</td> <td>Proficient user</td> <td>B2</td> <td>Independent user</td> <td>B2</td> <td>Independent user</td> <td>C1</td> <td>Proficient user</td> </tr> </tbody> </table>	Understanding				Speaking				Writing		Listening		Reading		Spoken interaction		Spoken production				B1	Independent user	C2	Proficient user	B2	Independent user	B2	Independent user	C1	Proficient user
Understanding				Speaking				Writing																							
Listening		Reading		Spoken interaction		Spoken production																									
B1	Independent user	C2	Proficient user	B2	Independent user	B2	Independent user	C1	Proficient user																						
	(*) Common European Framework of Reference for Languages																														
Qualification	Preliminary English Test (Council of Europe Level B1): Pass with Merit																														

Social skills and competences	I am a responsible person, I love relationships and I was able to unify these two aspects as member of the council of Italian professors of gastroenterology (COLMAD), as class representative from second to sixth years of medicine course. Autonomous, hard worker, quick learner.
Technical skills and competences	<ul style="list-style-type: none"> • Excellent knowledge of Microsoft operating systems, web browsing, Word, Excel, PowerPoint; basic knowledge of Access, Photoshop • Excellent skills in hardware, good in wireless networks • Excellent knowledge of the program for medical statistics MedCalc • Basic knowledge of programming, especially in C language • Basic knowledge of HTML and of web development
Other skills and competences	Technology, astronautics, current events, sports, economics.
Driving licence	Category B
Additional information	<p>Publications on Pubmed or WEB OF SCIENCE:</p> <ol style="list-style-type: none"> 1. Ribaldone DG, Astegiano M, Fagoonee S, Rizzetto M, Pellicano R. Epilepsy and celiac disease: review of literature. <i>Panminerva Med.</i> 2011;53:213-6. 2. Cammarota T, Ribaldone DG, Resegotti A, Repici A, Danese S, Fiorino G, et al. Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. <i>Scand J Gastroenterol.</i> 2013;48:552-5. 3. Pellicano R, De Angelis C, Ribaldone DG, Fagoonee S, Astegiano M. 2013 update on celiac disease and eosinophilic esophagitis. <i>Nutrients.</i> 2013;5:3329-36. 4. Savi L, Ribaldone DG, Fagoonee S, Pellicano R. Is <i>Helicobacter pylori</i> the Infectious Trigger for Headache?: a Review. <i>Infect Disord Drug Targets.</i> 2013;13:313-7. 5. Adriani A, Pantaleoni S, Luchino M, Ribaldone DG, Reggiani S, Sapone N, et al. Osteopenia and osteoporosis in patients with new diagnosis of inflammatory bowel disease. <i>Panminerva Med.</i> 2014;56:145-9. 6. Pantaleoni S, Luchino M, Adriani A, Pellicano R, Stradella D, Ribaldone DG, et al. Bone mineral density at diagnosis of celiac disease and after 1 year of gluten-free diet. <i>ScientificWorldJournal.</i> 2014;2014:173082. 7. Pellicano R, Ribaldone DG, Saracco GM, Leone N, De Angelis C, Arrigoni A, et al. Benefit of supplements in functional dyspepsia after treatment of <i>Helicobacter pylori</i>. <i>Minerva Gastroenterol Dietol.</i> 2014;60:263-8. 8. Ribaldone DG, Cammarota T, Resegotti A, Sarno A, Robotti D, Deboni P, et al. Power Doppler sonography to predict the risk of surgical recurrence of Crohn's disease. <i>Journal of Ultrasound.</i> 2014;18:51-5 9. Ribaldone DG, Cammarota T, Resegotti A, Astegiano M. A preserved stratified pattern of the bowel wall 1 year after major surgery does not influence the surgical recurrence of Crohn's disease. <i>Ir J Med Sci.</i> 2016;185:269-70. 10. Simondi D, Ribaldone DG, Bonagura GA, Foi S, Sapone N, Garavagno M, et al. <i>Helicobacter pylori</i> in celiac disease and in duodenal intraepithelial lymphocytosis: Active protagonist or innocent bystander? <i>Clin Res Hepatol Gastroenterol.</i> 2015;39:740-5. 11. Ribaldone DG, Fagoonee S, Astegiano M, Saracco G, Pellicano R. Efficacy of amoxicillin and clarithromycin-based triple therapy for <i>Helicobacter pylori</i> eradication: a 10-year trend in Turin, Italy. <i>Panminerva Med.</i> 2015;57:145-6. 12. Greco A, Caviglia GP, Brignolo P, Ribaldone DG, Reggiani S, Sguazzini C, et al. Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. <i>Scand J Gastroenterol.</i> 2015;50:1376-81. 13. Ribaldone DG, Garavagno M, Pellicano R, Bresso F, Fagoonee S, David E, et al. Prevalence and prognostic value of hepatic histological alterations in patients with Crohn's disease. <i>Scand J Gastroenterol.</i> 2015;50:1463-8. 14. Pellicano R, Bruno M, Fagoonee S, Ribaldone DG, Fasulo R, De Angelis C. Endoscopic ultrasound in the preoperative staging of gastric cancer: key messages for surgeons. <i>Minerva Chir.</i> 2015;70:417-27 15. Ribaldone DG, Fagoonee S, Astegiano M, De Angelis C, Smedile A, Caviglia GP, et al. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis. <i>Pain Physician.</i> 2015;18:599-607.

16. Ribaldone DG, Simondi D, Astegiano M, Pellicano R. On Inverse Association Between *Helicobacter pylori* Gastritis and Microscopic Colitis: The European Data. *Inflamm Bowel Dis.* 2016;22:E11-2.
17. Ribaldone DG, Conti L, Resegotti A, Astegiano M. Adnexal localization of Crohn's disease and recurrent massive ovary cysts. *Rev Esp Enferm Dig.* 2016;108.
18. Resegotti A, Silvestri S, Astegiano M, Deiro G, Ribaldone D, Cassine D, et al. "Small is beautiful" A series of ileo-anal anastomoses performed with the 25 - mm circular stapler. *Ann Ital Chir.* 2016;87:186-91.
19. Dellepiane S, Ribaldone DG. Pathogenesis of nephrotic syndrome after hematopoietic stem cell transplantations. *Minerva Med.* 2016;107:183-4.
20. Ribaldone DG, Fagoonee S, Colombini J, Saracco G, Astegiano M, Pellicano R. *Helicobacter Pylori* infection and asthma: Is there a direct or an inverse association? A meta-analysis. *World J Meta-Anal.* 2016;4:63-68.
21. Ribaldone DG, Fagoonee S, Hickman I, Altruda F, Saracco GM, Pellicano R. *Helicobacter pylori* infection and ischemic heart disease: could experimental data lead to clinical studies? *Minerva Cardioangiol.* 2016;64:686-96.
22. Ribaldone DG, Saracco G, Pellicano R. Response to: Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of *Helicobacter pylori*: A Comparative Study in a Cohort of Romanian Patients". *Gastroenterol Res Pract.* 2016;2016:4760378.
23. Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM, Mégraud F. A 2016 panorama of *Helicobacter pylori* infection: key messages for clinicians. *Panminerva Med.* 2016;58:304-17.
24. Bonagura GA, Ribaldone DG, Fagoonee S, Sapone N, Caviglia GP, Saracco GM, et al. Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitis")? *World J Gastrointest Pathophysiol.* 2016;7:307-13.
25. Ribaldone DG, Pellicano R. Prevalence of infectious agents in patients with systemic sclerosis: defining the control group. *Turk J Med Sci.* 2016;46:1611-2.
26. Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM. The first-line treatment of *Helicobacter pylori* infection in Piedmont in the year 2017. *Panminerva Med.* 2017;59:199.
27. Ribaldone DG, Saracco G, Pellicano R. Finally, it is bismuth's time. *Saudi J Gastroenterol.* 2017;23:127.
28. Ribaldone DG, Astegiano M, Pellicano R. The role of hepatic enzymes in Crohn's disease. *Int J Colorectal Dis.* 2017 Sep;32(9):1363-1364.
29. Ribaldone DG, Saracco G, Pellicano R. Does *Helicobacter pylori* infection increase the risk of adult-onset asthma? *Eur J Clin Microbiol Infect Dis.* 2017 Oct;36(10):1995-1996.
30. Ribaldone DG, Astegiano M, Saracco G, Pellicano R. Amoxicillin and Metronidazole Therapy for *Helicobacter pylori* Eradication: A 10-Year Trend in Turin, Italy. *Balkan Med J.* 2017;34:290-1.
31. Ribaldone DG, Petrini E. How to interpret meta-analysis results. *Panminerva Med.* 2017;59:274.
32. Ribaldone DG, Saracco GM. Food supplements, stress and gastrointestinal diseases. *Panminerva Med.* 2017;59:274-5.
33. Caviglia GP, Squazzini C, Cisarò F, Ribaldone DG, Rosso C, Fagoonee S, et al. Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clobopride: a "real world" study by ¹³C-octanoic acid breath test. *Minerva Med.* 2017 Dec;108(6):489-495.
34. Ribaldone DG, Simondi D, Manca A, Demarchi B, Pulitanò R, Astegiano M, et al. Features of inflammatory bowel disease followed in a second level center in Northern Italy. *Minerva Med.* 2017;108:481-2.
35. Astegiano M, Touscoz GA, Caviglia GP, Ribaldone DG, De Angelis C, Peyre S, et al. Non-organ-specific autoimmunity in patients suffering from gastric ulcer with and without *Helicobacter pylori* infection. *Minerva Biotechnologica* 2017;29:109-13
36. Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernerò M, et al. Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. *Ir J Med Sci.* 2017 Jul 29. doi: 10.1007/s11845-017-1666-0. [Epub ahead of print]
37. Ribaldone DG, Astegiano M. Biosimilar CT-P13 in treating ulcerative colitis in the real world. *Minerva Gastroenterol Dietol.* 2017;63:305-306.

38. Ribaldone DG, Saracco G, Pellicano R. Comment on *Helicobacter pylori* seroprevalence and the occurrence and severity of psoriasis. *An Bras Dermatol*. 2017 Jul-Aug;92(4):584.
39. Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. *J Med Virol*. 2018 Feb;90(2):320-327.
40. Ribaldone DG, Saracco GM, Pellicano R. *Helicobacter pylori* and proton pump inhibitor therapy: One diagnostic method is enough? *Eur J Intern Med*. 2017 Nov 4. pii: S0953-6205(17)30431-4. doi: 10.1016/j.ejim.2017.10.023. [Epub ahead of print]
41. Ribaldone DG, Manetta T, Mengozzi G, Saracco GM, Pellicano R, Astegiano M. Adalimumab trough levels predict Crohn's disease clinical course. *Dig Liver Dis*. 2017 Oct 28. pii: S1590-8658(17)31267-7. doi: 10.1016/j.dld.2017.09.139. [Epub ahead of print]
42. Ribaldone DG, Saracco GM, Pellicano R. Comments on Sulimani et al.: A weekly 35,000 IU vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females. *Arch Osteoporos*. 2017;12:102.
43. Ribaldone DG, Saracco GM, Pellicano R. Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery: What About Celiac Disease? *Obes Surg*. 2017 Nov 17. doi: 10.1007/s11695-017-3027-5. [Epub ahead of print]
44. Ribaldone DG, Bruno M, Solidoro P, De Angelis C. Real time visualization may be advisable to exclude aspiration in patients undergoing capsule endoscopy examination. *Rev Esp Enferm Dig*. 2017 Dec;109(12):878-879.
45. Ribaldone DG, Saracco GM, Pellicano R. Pediatric epilepsy and psychiatric comorbidity: could celiac disease diagnosis improve the outcome? *Minerva Pediatr*. 2017 Nov 21. doi: 10.23736/S0026-4946.17.05122-2. [Epub ahead of print]
46. Ribaldone DG, Saracco GM, Astegiano M, Pellicano R. Efficacy of infliximab biosimilars in patients with Crohn's disease. *Lancet*. 2017 Dec 2;390(10111):2435-2436. doi: 10.1016/S0140-6736(17)33047-7. Epub 2017 Dec 1.
47. Ribaldone DG, Saracco G, Astegiano M, Pellicano R. Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? *Aliment Pharmacol Ther*. 2018;47:146-147.
48. Ribaldone DG, Venero M, Saracco GM, Pellicano R, Finocchiaro F, Caviglia GP, Astegiano M. The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. *Scand J Gastroenterol*. 2017 Dec 11:1-6. doi: 10.1080/00365521.2017.1405070. [Epub ahead of print].
49. Ribaldone DG, Bruno M, Gaia S, Saracco GM, De Angelis C. Endoscopic ultrasound to diagnose pneumatosis cystoides intestinalis (with video). *Endosc Ultrasound*. 2017 Nov-Dec;6:416-417.
50. Ribaldone DG. Periodontal health and coronary heart disease: a comment. *Minerva Stomatol*. 2018;67:34-35.
51. Ribaldone DG, Saracco GM, Astegiano M, Pellicano R. Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results. *Aliment Pharmacol Ther*. 2018;47:448-449.
52. Pellicano R, Ribaldone DG, Astegiano M, Dughera L, Battaglia E, Morgando A, et al. Gastroenterology today: between certainties and news: a meeting held in Turin on May 27, 2017. *Minerva Gastroenterol Dietol*. 2018 Jan 10. doi: 10.23736/S1121-421X.18.02465-0. [Epub ahead of print]
53. Caviglia GP, Ribaldone DG, Rosso C, Saracco GM, Astegiano M, Pellicano R. Fecal calprotectin: beyond intestinal organic diseases. *Panminerva Med*. 2018;60:29-34.
54. Ribaldone DG, Saracco GM, Pellicano R. Comment on "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp". *Can J Gastroenterol Hepatol*. 2017;2017:4083272.
55. Ribaldone DG, Astegiano M, Pellicano R. *Helicobacter pylori* eradication: poor medical compliance from East to West of the world. *Scand J Gastroenterol*. 2018 Mar;53:265.
56. Ribaldone DG, Mazzucco D, Fagoonee S, Crocellà L, Lavagna A, Fracchia M, et al. Management of *Helicobacter pylori* in Piedmont, Italy. *Minerva Gastroenterol Dietol*. 2018 Sep;64(3):235-250.
57. Caviglia GP, Ribaldone DG, Abate ML, Ciancio A, Pellicano R, Smedile A, et al. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. *Scand J Gastroenterol*. 2018 Jun;53(6):734-740.

58. Ribaldone DG. Eosinophilic esophagitis and celiac disease. *Minerva Gastroenterol Dietol*. 2018 May 31. doi: 10.23736/S1121-421X.18.02504-7. [Epub ahead of print]
59. Ribaldone DG, Venero M, Astegiano M, Pellicano R. How ameliorate the adherence in patients with inflammatory bowel disease? *Scand J Gastroenterol*. 2018 Jul 3:1-2. doi: 10.1080/00365521.2018.1485731. [Epub ahead of print]
60. Ribaldone DG, Pellicano R, Actis GC. Inflammation: a highly conserved, Janus-like phenomenon - a gastroenterologist' perspective. *J Mol Med (Berl)*. 2018 Jul 9. doi: 10.1007/s00109-018-1668-z. [Epub ahead of print]
61. Caviglia GP, Olivero A, Rosso C, Bosco C, Ribaldone DG, Fagoonee S. Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma. *Minerva Biotechnologica* 2018;30:88-93.
62. Bruno M, Ribaldone DG, Fasulo R, Gaia S, Marietti M, Risso A, et al. Is there a link between periampullary diverticula and biliopancreatic disease? An EUS approach to answer the question. *Dig Liver Dis*. 2018 Aug 4. doi: 10.1016/j.dld.2018.07.034. [Epub ahead of print]
63. Caviglia GP, Dughera F, Ribaldone DG, Rosso C, Abate ML, Pellicano R, et al. Serum zonulin in patients with inflammatory bowel disease: a pilot study. *Minerva Med*. 2018 Aug 28. doi: 10.23736/S0026-4806.18.05787-7. [Epub ahead of print]
64. Ribaldone DG. Roux-en-Y Gastric Bypass and Celiac Disease : Gastric Bypass and Celiac Disease. *Obes Surg*. 2018;28:3638.
65. Pellicano R, Ribaldone DG. Osteoporosis, osteopenia, and inflammatory bowel disease: lessons from a real-world study. *Pol Arch Intern Med*. 2018;128:411-413.
66. Actis GC, Pellicano R, Ribaldone DG. A Concise History of Thiopurines for Inflammatory Bowel Disease: from Anecdotal Reporting to Treat-to-Target Algorithms. *Rev Recent Clin Trials*. 2018 Sep 10. doi: 10.2174/1574887113666180910120959. [Epub ahead of print]
67. Ribaldone DG, Pellicano R. Infections and stroke: Which potential pathogenic mechanism? *Int J Stroke*. 2018 Sep 10:1747493018801219. doi: 10.1177/1747493018801219. [Epub ahead of print]
68. Venero M, Ribaldone DG, Astegiano M, Pellicano R. Risk of incident melanoma in patients with inflammatory disease treated with anti-TNF: the Turin experience. *G Ital Dermatol Venereol*. 2018 Sep 20. doi: 10.23736/S0392-0488.18.06017-0. [Epub ahead of print]
69. Adriani A, Ribaldone DG, Astegiano M, Durazzo M, Saracco GM, Pellicano R. Irritable bowel syndrome: the clinical approach. *Panminerva Med*. 2018 Sep 24. doi: 10.23736/S0031-0808.18.03541-3. [Epub ahead of print]
70. Faletti R, Ribaldone DG, Gatti M, Perazzini C, Robella M, Angelino F, et al. Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn's disease. *Rev Esp Enferm Dig*. 2018 Oct 4;110. doi: 10.17235/reed.2018.5691/2018. [Epub ahead of print]
71. Senore C, Giovo I, Ribaldone DG, Ciancio A, Cassoni P, Arrigoni A, et al. Management of Pt1 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators. *Eur J Surg Oncol*. 2018;44(12):1873-1879.
72. Ribaldone DG. ACG Clinical Guideline on Crohn's Disease: A Point of View from Europe. *Am J Gastroenterol*. 2018 Nov 8. doi: 10.1038/s41395-018-0410-3. [Epub ahead of print]
73. Ribaldone DG, Fagoonee S. Comments on Umer Draz et al. (J Pak Med Assoc. 2018; 68: 939-41) Presence of pre-diabetes in Helicobacter pylori positive versus Helicobacter pylori negative patients having dyspepsia. *J Pak Med Assoc*. 2018;68:1734.
74. Venero M, Astegiano M, Ribaldone DG. New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series. *Am J Gastroenterol*. 2019;114:179-180.
75. Ribaldone DG, Venero M, Pellicano R. Is microbiome a target for the management of allergy associated diseases in children? *Eur Rev Med Pharmacol Sci*. 2018;22:8061-8062.
76. Pellicano R, Cisarò F, Durazzo M, Ribaldone DG. When is it useful to act on microbiota in atopic children? A recent experience. *Minerva Pediatr*. 2019;71:1-3.
77. Ribaldone DG, Resegotti A, Astegiano M. The therapy of chronic pouchitis. *Minerva Gastroenterol Dietol*. 2019 Jan 4. doi: 10.23736/S1121-421X.18.02551-5. [Epub ahead of print]
78. Marzano A, Angelucci E, Astegiano M, Baratelli C, Biancone L, Bironzo P, et al. AISF position paper on HCV in immunocompromised patients. *Digestive and Liver Disease* 2019;51:10-23.

79. Ribaldone DG, Astegiano M. Comment #2 on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin". *Gastroenterol Res Pract.* 2018;2018:5260358.
80. Ribaldone DG, Pellicano R. Comment on "Factors Associated with Recurrent Ulcers in Patients with Gastric Surgery after More Than 15 Years: A Cross-Sectional Single-Center Study". *Gastroenterol Res Pract.* 2018;2018:8356948.
81. Ribaldone DG, Simondi D, Petrini E, Astegiano M, Durazzo M. Non-invasive biomarkers for gastric cancer diagnosis: ready for prime time? *Minerva Biotechnologica* 2019;31:3-10.
82. Ribaldone DG, Fagoonee S, Astegiano M, Durazzo M, Morgando A, Sprujevnik T, et al. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. *J Clin Med.* 2019;8(2).
83. Ribaldone DG. Treatment of Helicobacter pylori infection in Piedmont: new preliminary data on prescription attitudes. *Minerva Gastroenterol Dietol.* 2019 Feb 12. doi: 10.23736/S1121-421X.19.02550-9. [Epub ahead of print]
84. Ribaldone DG, Resegotti A, Pellicano R, Astegiano M, Saracco GM, Morino M. The role of topical therapy for perianal fistulizing Crohn's disease: are we forgetting something? *Minerva Gastroenterol Dietol.* 2019 Feb 12. doi: 10.23736/S1121-421X.19.02565-0. [Epub ahead of print]
85. Ribaldone DG, Venero M, Pellicano R. Helicobacter pylori prevalence: Are the data totally reliable? *J Pediatr Surg.* 2019 Feb 16. pii: S0022-3468(19)30091-0. doi: 10.1016/j.jpedsurg.2018.12.026. [Epub ahead of print]
86. Venero M, Boano V, Ribaldone DG, Pellicano R, Astegiano M. Oral iron supplementation with Feralgine® in inflammatory bowel disease: a retrospective observational study. *Minerva Gastroenterol Dietol.* 2019 Mar 27. doi: 10.23736/S1121-421X.19.02572-8. [Epub ahead of print]
87. Ribaldone DG, Pellicano R, Venero M, Caviglia GP, Saracco GM, Morino M, et al. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. *Scand J Gastroenterol.* 2019;54(4):407-413.
88. Fiorino G, Caprioli F, Daperno M, Mocchiari F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients' association representatives. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis.* 2019;51(5):632-639.
89. Ribaldone DG, Pellicano R, Actis GC. The gut and the Inflammatory Bowel Diseases inside-out: the extra-intestinal manifestations. *Minerva Gastroenterol Dietol.* 2019 Apr 16. doi: 10.23736/S1121-421X.19.02577-7. [Epub ahead of print]
90. Ribaldone DG, Pellicano R. Helicobacter pylori eradication: the relevance of a periodic update. *Ann Gastroenterol.* 2019 May-Jun;32(3):320.
91. Ribaldone DG, Pellicano R. Gut microbiota and chronic exercise in diabetic patients: not only bacteria. *Minerva Med.* 2019 May 6. doi: 10.23736/S0026-4806.19.06090-7. [Epub ahead of print]
92. Ribaldone DG, Fagoonee S. Helicobacter pylori Resistance: A Medical Predictive Factor of Response. *Arch Iran Med.* 2019;22(4):221.
93. Ribaldone DG, Adriani A, Caviglia GP, Nicolò A, Agnesod D, Simiele M, Riganò D, Pellicano R, Canaparo R, Perri GD, D'Avolio A, Luzza F, Saracco GM, Astegiano M. Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. *Medicina (Kaunas).* 2019;55(8). pii: E441.
94. Ribaldone DG, Pellicano R, Actis GC. Inflammation in gastrointestinal disorders: prevalent socioeconomic factors. *Clin Exp Gastroenterol.* 2019;12:321-329.
95. Marinoni C, Ribaldone DG, Rosso C, Astegiano M, Caviglia GP. Diagnosis of Helicobacter pylori infection: A look into molecular aspects of urea breath test. *Minerva Biotechnologica.* 2019; 31(3):100-107.
96. Caviglia GP, Rosso C, Ribaldone DG, Dughera F, Fagoonee S, Astegiano M, Pellicano R. Physiopathology of intestinal barrier and the role of zonulin. *Minerva Biotechnologica.* 2019;31(3):83-92.
97. Armandi A, Bonetto S, Pellicano R, Caviglia GP, Astegiano M, Saracco GM, Ribaldone DG. Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message. *Minerva Biotechnologica.* 2019;31(3):93-99.

98. Ribaldone DG, Vernero M, Parisi S, Ditto MC, Pellicano R, Morino M, Saracco GM, Fusaro E, Astegiano M. Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients. *Scand J Gastroenterol.* 2019 Sep 24;1-4. doi: 10.1080/00365521.2019.1668052. [Epub ahead of print]
99. Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, Fusaro E, Saracco GM, Astegiano M. Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. *J Clin Med.* 2019;8(10). pii: E1646.
100. Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, Ghalim F, Carbonnel F, Verstockt B, Festa S, Maia L, Berrozpe A, Zagorowicz E, Savarino E, Ellul P, Vavricka SR, Calvo M, Koutroubakis I, Hoentjen F, Salazar LF, Callela F, Cañete Pizarro F, Soufleris K, Sonnenberg E, Cavicchi M, Wypych J, Hommel C, Ghiani A, Fiorino G; ECCO CONFERENCE COMMITTEE. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. *J Crohns Colitis.* 2020;14(4):480-489.
101. Ribaldone DG, Caviglia GP, Pellicano R, Vernero M, Italia A, Morino M, Saracco GM, Astegiano M. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index. *Scand J Gastroenterol.* 2019 Nov;54(11):1339-1345.
102. Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. *J Clin Med.* 2019 Nov 14;8(11). pii: E1970.
103. Petrini E, Caviglia GP, Pellicano R, Saracco GM, Morino M, Ribaldone DG. Risk of drug interactions and prescription appropriateness in elderly patients. *Ir J Med Sci.* 2019 Nov 30. doi: 10.1007/s11845-019-02148-8. [Epub ahead of print]
104. Ribaldone DG, Pellicano R, Saracco GM, Morino M, Astegiano M. Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis. *Rev Esp Enferm Dig.* 2020 Jan;112(1):59-63.
105. Ribaldone DG, Pellicano R. Bariatric Surgery and Inflammatory Bowel Disease: a Role for Microbiota? *Obes Surg.* 2020 Mar;30(3):1143-1144.
106. Giudici G, Ribaldone DG, Astegiano M, Saracco GM, Pellicano R. Eosinophilic colitis: clinical review and update 2020. *Minerva Gastroenterol Dietol.* 2020 Jan 28. doi: 10.23736/S1121-421X.20.02656-2. [Epub ahead of print]
107. Caviglia GP, Olivero A, Ciancio A, Tandoi F, Troshina G, Rosso C, Abate ML, Younes R, Ribaldone DG, Smedile A, Rizzetto M, Romagnoli R, Saracco GM, Bugianesi E. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. *Diagn Microbiol Infect Dis.* 2020 Apr;96(4):114985.
108. Ribaldone DG, Caviglia GP, Pellicano R, Vernero M, Saracco GM, Morino M, Astegiano M. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. *Rev Esp Enferm Dig.* 2020 Mar;112(3):195-200.
109. Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. *J Clin Med.* 2020 Feb 19;9(2). pii: E563.
110. Caviglia GP, Rosso C, Stalla F, Rizzo M, Massano A, Abate ML, Olivero A, Armandi A, Vanni E, Younes R, Fagoonee S, Pellicano R, Astegiano M, Saracco GM, Bugianesi E, Ribaldone DG. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. *J Clin Med.* 2020 Mar 15;9(3). pii: E800.
111. Rizza S, Mistrangelo M, Ribaldone DG, Morino M, Astegiano M, Saracco GM, Pellicano R. Proctitis: a glance beyond inflammatory bowel diseases. *Minerva Gastroenterol Dietol.* 2020 Mar 24. doi: 10.23736/S1121-421X.20.02670-7. [Epub ahead of print]
112. Ribaldone DG, Procopio M, Pellicano R, Barale M, Giudici G, Morino M, Saracco GM, Astegiano M. Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score. *Minerva Gastroenterol Dietol.* 2020 Mar 24. doi: 10.23736/S1121-421X.20.02672-0. [Epub ahead of print]
113. Rosso C, Caviglia GP, Younes R, Foglia B, Blanco MJG, Ribaldone DG, Bugianesi E. Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease. *Clin Lab.* 2020 Apr 1;66(4).
114. Ribaldone DG. Inflammatory bowel disease and pancreatic diseases. *Minerva Gastroenterol Dietol.* 2020 Mar;66(1):6-7.

115. Pellicano R, Ribaldone DG, Caviglia GP. Strategies for *Helicobacter pylori* eradication in the year 2020. *Saudi J Gastroenterol*. 2020 Apr 16. doi: 10.4103/sjg.SJG_95_20. [Epub ahead of print]
116. Phillips FM, Verstockt B, Sebastian S, Ribaldone DG, Vavricka S, Katsanos K, Slattery E, de Suray N, Flores C, Fries W, Vincenzi F, Capoferro E, Bachmann O, Kopylov U; ECCO CONFER investigators. Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series. *J Crohns Colitis*. 2020 Apr 22. pii: jjaa078. doi: 10.1093/ecco-jcc/jjaa078. [Epub ahead of print]
117. Ribaldone DG, Astegiano M, Actis GC, Pellicano R. Management of inflammatory bowel disease during COVID-19 pandemic. *Minerva Gastroenterol Dietol*. 2020 Apr 23. doi: 10.23736/S1121-421X.20.02707-5. [Epub ahead of print]
118. Colombo G, Clemente N, Zito A, Bracci C, Colombo FS, Sangaletti S, Jachetti E, Ribaldone DG, Caviglia GP, Pastorelli L, De Andrea M, Naviglio S, Lucafò M, Stocco G, Grolla AA, Campolo M, Casili G, Cuzzocrea S, Esposito E, Malavasi F, Genazzani AA, Porta C, Travelli C. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. *J Mol Med (Berl)*. 2020;98(4):595-612.
119. Venero M, Ribaldone DG, Cariti C, Ribero S, Susca S, Astegiano M, Dapavo P. Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease. *J Dermatol*. 2020 Jun;47(6):e216-e217.
120. Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini M, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. *Gut*. 2020 Jul;69(7):1213-1217.
121. Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. *J Clin Med*. 2020;9(5):E1323.
122. Carli E, Caviglia GP, Pellicano R, Fagoonee S, Rizza S, Astegiano M, Saracco GM, Ribaldone DG. Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. *Medicina (Kaunas)*. 2020;56(6):E285.
123. Ribaldone DG, Brigo S, Mangia M, Saracco GM, Astegiano M, Pellicano R. Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity. *Medicines (Basel)*. 2020;7(6):E33.
124. Mosso E, Bonetto S, Longobardi G, Abenavoli L, Ribaldone DG, Saracco GM, Pellicano R. Management of functional dyspepsia in the year 2020. A clinical point of view [published online ahead of print, 2020 Jul 3]. *Minerva Gastroenterol Dietol*. 2020;10.23736/S1121-421X.20.02732-4. doi:10.23736/S1121-421X.20.02732-4
125. Benfaremo D, Luchetti MM, Di Carlo M, Laganà B, Picchianti-Diamanti A, Carubbi F, Pica R, Chimenti MS, Lorenzetti R, Scolieri P, Bruzzese V, Benedetti A, Ramonda R, Giacomelli R, Salaffi F, Gabrielli A; GRADES-IBD Study Group. Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases. *J Rheumatol*. 2021 Feb;48(2):179-187. doi: 10.3899/jrheum.200364. Epub 2020 Jul 15. PMID: 32669448.
126. Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A, Ribaldone DG, Buda A, Bezzio C, Fiorino G, Fantini MC, Scaldaferrì F, Guidi L, Danese S, Gasbarrini A, Orlando A, Armuzzi A. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease [published online ahead of print, 2020 Jul 17]. *J Crohns Colitis*. 2020;jjaa149.
127. Ribaldone DG, Bruno M, Gaia S, Cantamessa A, Bragoni A, Caropreso P, Sacco M, Fagoonee S, Saracco GM, De Angelis C. Differential diagnosis of pancreatic cysts: A prospective study on the role of intra-cystic glucose concentration. *Dig Liver Dis*. 2020 Sep;52(9):1026-1032.
128. Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, Abate ML, Olivero A, Armandi A, Vanni E, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with *Bifidobacterium Longum* ES1 for 8 or 12 Weeks: A Preliminary Report. *J Clin Med*. 2020;9(8):E2353.

129. Rosso C, Caviglia GP, Younes R, Ribaldone DG, Fagoonee S, Pellicano R, Bugianesi E. Molecular mechanisms of hepatic fibrosis in chronic liver diseases. *Minerva Biotechnologica* 2020 September;32(3):121-7.
130. Ribaldone DG, Rajesh P, Chandradhara D, Astegiano M, Pellicano R. A randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and tolerability of a novel oral bioadhesive formulation for the treatment of nonerosive reflux disease-related symptoms [published online ahead of print, 2020 Aug 14]. *Eur J Gastroenterol Hepatol*. 2020;10.1097/MEG.0000000000001888.
131. Actis GC, Ribaldone DG, Pellicano R. Landing of the new Coronavirus to Italian shores: it is mandatory to make the most from the Chinese experience. *Minerva Pneumologica* 2020 June;59(2):21-3.
132. Actis GC, Pellicano R, Ribaldone DG. Inflammation: an all-season phenomenon in human pathology. *Gazzetta Medica Italiana - Archivio per le Scienze Mediche* 2020;179(7-8):435-6.
133. Ribaldone DG, Imperatore N, Le Grazie M, Furfaro F, Balestrieri P, De Blasio F, Fagoonee S, Mosso E, Boano V, Reggio D, Sarli E, Castiglione F, Milla M, Vecchi M, Saracco GM, Salizzoni M, Romagnoli R, Fiorino G, Astegiano M; Italian Group for the study of Inflammatory Bowel Disease IG-IBD. Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. *Dig Liver Dis*. 2020 Sep 21:S1590-8658(20)30503-X.
134. Ciancio A, Ribaldone DG, Dotta A, Giordanino C, Sacco M, Fagoonee S, Pellicano R, Saracco GM. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis c successfully treated with direct acting antiviral agents. *Liver Int*. 2020 Sep 30. doi: 10.1111/liv.14676. Epub ahead of print. PMID: 32998174.
135. Caviglia GP, Ciruolo M, Olivero A, Carucci P, Rolle E, Rosso C, Abate ML, Risso A, Ribaldone DG, Tandoi F, Saracco GM, Bugianesi E, Gaia S. Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. *Cancers (Basel)*. 2020 Sep 28;12(10):E2776. doi: 10.3390/cancers12102776. PMID: 32998218.
136. Fantini MC, Biancone L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Guglielmi FW, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Di Ruscio M, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Saibeni S, Fiorino G. Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. *Inflamm Bowel Dis*. 2020 Oct 23;26(11):e134-e136. doi: 10.1093/ibd/izaa254. PMID: 33029612.
137. Saibeni S, Scucchi L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Mazzuoli S, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Ruscio MD, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Fantini MC, Fiorino G; IG-IBD (Italian Group for the study of Inflammatory Bowel Disease). Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. *United European Gastroenterol J*. 2020 Oct 18:2050640620964132.
138. Armandi A, Rosso C, Ribaldone DG, Caviglia GP. Moving towards core antigen for the management of patients with overt and occult HBV infection. *Panminerva Med*. 2020 Oct 19. doi: 10.23736/S0031-0808.20.04163-4. Epub ahead of print. PMID: 33073556.
139. Actis GC, Ribaldone DG, Fagoonee S, Pellicano R. COVID-19: a user's guide, status of the art, and an original proposal to terminate viral recurrence. *Minerva Med*. 2020 Oct 26. doi: 10.23736/S0026-4806.20.07054-8. Epub ahead of print. PMID: 33104300.
140. Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. *Cancers (Basel)*. 2020 Oct 31;12(11):3218. doi: 10.3390/cancers12113218. PMID: 33142893.

141. Ribaldone DG, Venero M, Astegiano M. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: The extrapolation concept. *Rev Esp Enferm Dig.* 2020 Nov 19. doi: 10.17235/reed.2020.7253/2020. Epub ahead of print. PMID: 33207912.
142. Ciancio A, Ribaldone DG, Sacco M, Saracco GM. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C. *Liver Int.* 2020 Nov 22. doi: 10.1111/liv.14738. Epub ahead of print. PMID: 33222363.
143. Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocchi G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosentino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. *United European Gastroenterol J.* 2020 Dec 1:2050640620977405. doi: 10.1177/2050640620977405. Epub ahead of print. PMID: 33259773.
144. Stalla FM, Astegiano M, Ribaldone DG, Saracco GM, Pellicano R. The small intestine: barrier, permeability and microbiota. Key messages for clinicians. *Minerva Gastroenterol Dietol.* 2020 Dec 3. doi: 10.23736/S1121-421X.20.02808-1. Epub ahead of print. PMID: 33267569.
145. Caviglia GP, Rosso C, Armandi A, Gaggini M, Carli F, Abate ML, Olivero A, Ribaldone DG, Saracco GM, Gastaldelli A, Bugianesi E. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. *Int J Mol Sci.* 2020 Nov 22;21(22):8838. doi: 10.3390/ijms21228838. PMID: 33266488; PMCID: PMC7700603.
146. Ribaldone DG, Venero M, Caviglia GP. Targeting IL-10, ZO-1 gene expression and IL-6/STAT-3 trans-signalling by a combination of atorvastatin and mesalazine to enhance anti-inflammatory effects and attenuate progression of oxazolone-induced colitis. *Fundam Clin Pharmacol.* 2020 Dec 8. doi: 10.1111/fcp.12638. Epub ahead of print. PMID: 33289917.
147. Venero M, De Blasio F, Ribaldone DG, Bugianesi E, Pellicano R, Saracco GM, Astegiano M, Caviglia GP. The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. *J Clin Med.* 2020 Dec 4;9(12):3941.
148. Rosso C, Caviglia GP, Armandi A, Abate ML, Olivero A, Ribaldone DG, Pellicano R, Saracco GM, Bugianesi E. Performance of cytokeratin-18 apoptotic fragment for the identification of hepatic fibrosis and inflammation in patients with chronic viral hepatitis: a meta-analysis. *Minerva Biotechnologica* 2020 December;32(4):188-94.
149. Rosso C, Caviglia GP, Armandi A, Ribaldone DG, Bugianesi E. Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease? *Clin Res Hepatol Gastroenterol.* 2021 Jan 10:101611. doi: 10.1016/j.clinre.2020.101611. Epub ahead of print. PMID: 33441256.
150. Ribaldone DG, Pellicano R. Causes of childhood epilepsy: a look for celiac disease? *Gazzetta Medica Italiana - Archivio per le Scienze Mediche* 2020 December;179(12):679-80.
151. Caviglia GP, Armandi A, Rosso C, Ribaldone DG, Pellicano R, Fagoonee S. Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. *Diagnostics (Basel).* 2021 Jan 28;11(2):187. doi: 10.3390/diagnostics11020187. PMID: 33525443; PMCID: PMC7910971.
152. Caviglia GP, Rosso C, Armandi A, Ribaldone DG, Pellicano R, Bugianesi E. Analytical and clinical comparison between two different chemiluminescent enzyme immunoassays for the measurement of C-peptide in serum. *Minerva Biotechnology and Biomolecular Research* 2021 March;33:6-11.
153. Gaia S, Ciruolo M, Ribaldone DG, Rolle E, Migliore E, Mosso E, Vola S, Risso A, Fagoonee S, Saracco GM, Carucci P. Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma. *Curr Oncol.* 2021 Feb 25;28(2):1034-1044.
154. Baima G, Massano A, Squillace E, Caviglia GP, Buduneli N, Ribaldone DG, Aimetti M. Shared microbiological and immunological patterns in periodontitis and IBD: A scoping review. *Oral Dis.* 2021 Mar 10. doi: 10.1111/odi.13843. Epub ahead of print.
155. Rosso C, Aaron AA, Armandi A, Caviglia GP, Venero M, Saracco GM, Astegiano M, Bugianesi E, Ribaldone DG. Inflammatory Bowel Disease Nurse—Practical Messages. *Nursing Reports.* 2021; 11(2):229-241.

156. Caviglia GP, Abate ML, Rolle E, Carucci P, Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM, Ciancio A, Bugianesi E, Gaia S. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. *Biology (Basel)*. 2021 Mar 11;10(3):215
157. Bertani L, Ribaldone DG, Bellini M, Mumolo MG, Costa F. Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions? *Nutrients*. 2021 Apr 20;13(4):1387.
158. Resál T, Bor R, Szántó K, Fábíán A, Rutka M, Sacco M, Ribaldone DG, Molander P, Nancey S, Kopylov U, Vavrícka S, Drobne D, Lukas M, Farkas K, Szepes Z, Molnár T. Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey. *Therap Adv Gastroenterol*. 2021 Apr 22;14:17562848211006678.
159. Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. *Cancers (Basel)*. 2021 May 11;13(10):2305.
160. Alshesh A, Taylor J, Savarino EV, Truyens M, Armuzzi A, Ribaldone DG, Shitrit AB, Fibelman M, Molander P, Liefferinckx C, Nancey S, Korani M, Rutka M, Barreiro-de Acosta M, Domislovic V, Suris G, Eriksson C, Alves C, Mpitouli A, di Jiang C, Tepeš K, Coletta M, Foteinogiannopoulou K, Gisbert JP, Amir-Barak H, Attauabi M, Seidelin J, Afif W, Marinelli C, Lobaton T, Pugliese D, Maharshak N, Cremer A, Limdi JK, Molnár T, Otero-Alvarin B, Krznicar Z, Magro F, Karmiris K, Raine T, Drobne D, Koutroubakis I, Chaparro M, Yanai H, Burisch J, Kopylov U. Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. *J Clin Med*. 2021 Jun 29;10(13):2914.
161. Colombini J, Spadola Bisetti M, Albera R, Ribaldone DG, Saracco GM, Pellicano R. Use of reflux finding score and reflux symptom index for the management of laryngopharyngeal lesions: a pilot study. *Minerva Gastroenterol (Torino)*. 2021 Jul 9. doi: 10.23736/S2724-5985.21.02970-3. Epub ahead of print. PMID: 34240594.
162. Alshesh A, Eder P, Ribaldone DG, Oldenburg B, de Boer NK, Mantzaris GJ, Savarino EV, Dragoni G, Weisshof R, Truyens M, Festa S, Maillard MH, Capirchio L, Filip R, Theodoraki E, Kopylov U. Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFERENCE Multicenter Case Series. *J Crohns Colitis*. 2021 Jul 18;jjab124. doi: 10.1093/ecco-jcc/jjab124.
163. Ribaldone DG, Zurlo C, Fagoonee S, Rosso C, Armandi A, Caviglia GP, Saracco GM, Pellicano R. A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. *Life (Basel)*. 2021 Jul 4;11(7):650. doi: 10.3390/life11070650.
164. Caviglia GP, Martini G, Armandi A, Rosso C, Vernerio M, Bugianesi E, Astegiano M, Saracco GM, Ribaldone DG. Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. *J Clin Med*. 2021 Jul 23;10(15):3257. doi: 10.3390/jcm10153257.
165. Ribaldone DG, Tribocco E, Rosso C, Armandi A, Vernerio M, Bugianesi E, Astegiano M, Saracco GM, Caviglia GP. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. *J Clin Med*. 2021 Jul 30;10(15):3387.
166. Ditto MC, Parisi S, Landolfi G, Borrelli R, Realmuto C, Finucci A, Caviglia GP, Ribaldone DG, Astegiano M, Zanetti A, Carrara G, Scirè CA, Antivalle M, Sarzi-Puttini P, Fusaro E. Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis. *RMD Open*. 2021 Sep;7(3):e001755.
167. Phillips F, Verstockt B, Ribaldone DG, Guerra I, Teich N, Katsanos K, Filip R, Molnar T, Karmiris K. Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease: an ECCO CONFERENCE case series. *J Crohns Colitis*. 2021 Sep 11;jjab164.
168. Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciano F, Privitera AC, Simondi D, Giuffrida E, D'Inca R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. *Dig Liver Dis*. 2021 Sep 16:S1590-8658(21)00761-1.

169. Francavilla A, Gagliardi A, Piaggieschi G, Tarallo S, Cordero F, Pensa RG, Impeduglia A, Caviglia GP, Ribaldone DG, Gallo G, Grioni S, Ferrero G, Pardini B, Naccarati A. Faecal miRNA profiles associated with age, sex, BMI, and lifestyle habits in healthy individuals. *Sci Rep.* 2021 Oct 19;11(1):20645. doi: 10.1038/s41598-021-00014-1. PMID: 34667192; PMCID: PMC8526833.
170. Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. *Aliment Pharmacol Ther.* 2021 Oct 25.
171. Goessens L, Colombel JF, Outtier A, Ferrante M, Sabino J, Judge C, Saeidi R, Rabbitt L, Armuzzi A, Domenech E, Michalopoulos G, Cremer A, Garcia-Alonso FJ, Molnar T, Karmiris K, Gecse K, Van Oostrom J, Löwenberg M, Farkas K, Atreya R, Ribaldone DG, Selinger C, Hoentjen F, Bihin B, Sebastian S; European COMBIO study group, Rahier JF. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. *United European Gastroenterol J.* 2021 Oct 25. doi: 10.1002/ueg2.12170. Epub ahead of print. PMID: 34694746.
172. Bezzio C, Venero M, Ribaldone DG, Manes G, Saibeni S. Insights into the role of gastrointestinal ultrasound in ulcerative colitis. *Therap Adv Gastroenterol.* 2021 Oct 22;14:17562848211051456.
173. Caviglia GP, De Blasio F, Venero M, Armandi A, Rosso C, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. *J Clin Med.* 2021 Oct 26;10(21):4961.
174. Armandi A, Rosso C, Caviglia GP, Ribaldone DG, Bugianesi E. The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. *Front Endocrinol (Lausanne).* 2021 Nov 10;12:716533.
175. Festa S, Zerboni G, Derikx LAAP, Ribaldone DG, Dragoni G, Buskens C, van Dijkum EN, Pugliese D, Panzuto F, Krela-Kaźmierczak I, Reiss Mintz H, Shritrit AB, Chaparro M, Gisbert JP, Kopylov U, Teich N, Vainer E, Nagtegaal I, Hoentjen F, Garcia MJ, Filip R, Foteinogiannopoulou K, Koutroubakis IE, Argollo M, van Wanrooij RLJ, Laja H, Lobaton T, Truyens M, Molnar T, Savarino E, Aratari A, Papi C, Goren I. Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. *J Crohns Colitis.* 2021 Dec 1;jjab217.
176. Caviglia GP, Ribaldone DG, Nicolosi A, Pellicano R. Cytokines and Biologic Therapy in Patients with Inflammatory Bowel Diseases. *Gastroenterology Insights.* 2021; 12(4):443-445.
177. Actis GC, Pellicano R, Ribaldone DG. SARS-CoV-2: Impacts and Echoes. *Rev Recent Clin Trials.* 2021 Dec 21. doi: 10.2174/1574887117666211221170715. Epub ahead of print.
178. Cusato J, Bertani L, Antonucci M, Tomasello C, Caviglia GP, Dibitetto S, Massano A, Mangia M, Mula J, Ceccarelli L, Costa F, Zanzi F, Astegiano M, Ribaldone DG, D'Avolio A. Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. *Pharmaceuticals (Basel).* 2021 Nov 27;14(12):1230.
179. Armandi A, Rosso C, Nicolosi A, Caviglia GP, Abate ML, Olivero A, D'Amato D, Venero M, Gaggini M, Saracco GM, Ribaldone DG, Leeming DJ, Gastaldelli A, Bugianesi E. Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. *J Clin Med.* 2022 Jan 27;11(3):635.
180. Actis GC, Ribaldone DG, Pellicano R. COVID vaccine's hot problems: erratic serious blood clotting, ill-defined prion-like reactogenicity of the spike, unclear roles of other factors. *Minerva Med.* 2021 Dec;112(6):695-697.
181. Ribaldone DG, Pellicano R, Fagoonee S, Actis GC. Modulation of the gut microbiota: opportunities and regulatory aspects. *Minerva Gastroenterol (Torino).* 2022 Feb 18.
182. Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. *Dig Liver Dis.* 2022 Feb 17:S1590-8658(22)00137-2.

183. Gaia S, Rizza S, Bruno M, Ribaldone DG, Maletta F, Sacco M, Pacchioni D, Rizzi F, Saracco GM, Fagoonee S, De Angelis CG. Impact of Macroscopic On-Site Evaluation (MOSE) on Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Biopsy (EUS-FNB) of Pancreatic and Extrapaneatic Solid Lesions: A Prospective Study. *Diagnostics (Basel)*. 2022 Feb 7;12(2):428.
184. Ciancio A, Ribaldone DG, Salamone R, Bruno M, Caronna S, Debernardi Venon W, Giordanino C, Mondardini A, Musso A, Pennazio M, Rolle E, Sacco M, Sprujevnik T, De Angelis C, Saracco GM. Screening and surveillance of esophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct acting antiviral agents. *Liver Int*. 2022 Feb 26.
185. Baima, G., Ribaldone, D.G., Muwalla, M. et al. Can Periodontitis Affect the Health and Disease of the Digestive System? A Comprehensive Review of Epidemiological Evidence and Biological Mechanisms. *Curr Oral Health Rep*. 2021;8:96–106.
186. Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. COVID-19 and the enteric system: rapidly propagating issues. *Minerva Med*. 2022 Mar 22. doi: 10.23736/S0026-4806.22.08077-6.
187. Ribaldone DG, Caviglia GP, Gaia S, Rolle E, Risso A, Campion D, Brunocilla PR, Saracco GM, Carucci P. Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. *Curr Oncol*. 2022 Feb 24;29(3):1422-1429.
188. Bergamaschi G, Castiglione F, D'Inca R, Astegiano M, Fries W, Milla M, Ciacci C, Rizzello F, Saibeni S, Ciccocioppo R, Orlando A, Bossa F, Principi M, Vernia P, Ricci C, Scribano ML, Bodini G, Mazzucco D, Bassotti G, Riegler G, Buda A, Neri M, Caprioli F, Monica F, Manca A, Villa E, Fiorino G, Comberlato M, Aronico N, Della Corte C, Caccaro R, Gionchetti P, Giuffrida P, Iovino P, Lenti MV, Mengoli C, Pellegrini L, Pieraccini A, Ribaldone D, Testa A, Ubezio C, Viola A, Vecchi M, Klersy C, Di Sabatino A. Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. *Inflamm Bowel Dis*. 2022 Apr 2;izac054. doi: 10.1093/ibd/izac054.
189. Meineri G, Martello E, Radice E, Bruni N, Saettoni V, Atuahene D, Armandi A, Testa G, Ribaldone DG. Chronic Intestinal Disorders in Humans and Pets: Current Management and the Potential of Nutraceutical Antioxidants as Alternatives. *Animals (Basel)*. 2022 Mar 23;12(7):812.
190. Venero M, Ribaldone DG, Astegiano M, Pellicano R. The recipe for the perfect inflammatory bowel disease nurse in a northern Italy tertiary IBD centre: going beyond clinical care. *Minerva Gastroenterol (Torino)*. 2022 Apr 19.
191. Olivero A, Rosso C, Ciancio A, Abate ML, Nicolosi A, Troshina G, Armandi A, Ribaldone DG, Saracco GM, Bugianesi E, Rizzetto M, Caviglia GP. Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. *Biomedicines*. 2022 Mar 29;10(4):792.
192. Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone Livia, Nardone Olga Maria, Imperatore N, Fiorino G, Cappello M, Viola A, Mb P, C B, A A, S C, S M, F M, L G, G B, Ribaldone D, G M, A M, L M, A F, M G, L S, S S, W F, F C, A A, Mc F; IG-IBD. Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors. *Am J Gastroenterol*. 2022 Apr 13.
193. Resegotti A, Ribaldone DG. Is a protective stoma mandatory in anti-TNF-treated Crohn's disease patients undergoing surgery? *Gastroenterology*. 2022 Apr 30:S0016-5085(22)00459-0.
194. Caviglia GP, Ribaldone DG. Special Issue "Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice". *J Clin Med*. 2022 May 16;11(10):2797.
195. Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A; IG-IBD LIVE Study Group. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. *Aliment Pharmacol Ther*. 2022 Jul;56(1):95-109.
196. Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, Fiorino G, Drobne D, Kurent T, Yassin S, Maharshak N, Castiglione F, de Sire R, Nardone OM, Farkas K, Molnar T, Krznaric Z, Brinar M, Chashkova E, Livne Margolin M, Kopylov U, Bezzio C, Shitrit AB, Lukas M, Chaparro M, Truyens M, Nancey S, Lobaton T, Gisbert JP, Saibeni S, Bacsúr P, Bossuyt P, Schulberg J, Hoentjen F, Viganò C, Palermo A, Torres J, Revés J, Karmiris K, Velegraki M, Savarino E, Markopoulos P, Tsironi E, Ellul P, Suárez CC, Weisshof R, Ben-Hur D, Naftali T, Eriksson C, Koutroubakis IE, Foteinogiannopoulou K, Limdi JK, Liu E, Surís G, Calabrese E, Zorzi F, Filip R, Ribaldone DG, Snir Y, Goren I, Banai-Eran H,

- Broytman Y, Barak HA, Avni-Biron I, Ollech JE, Dotan I, Aharoni Golan M. Endoscopic Postoperative Recurrence In Crohn's Disease After Curative Ileocecal Resection With Early Prophylaxis By Anti-Tnf, Vedolizumab Or Ustekinumab: A Real-World Multicenter European Study. *J Crohns Colitis*. 2022 Jul 27;jjac100. doi: 10.1093/ecco-jcc/jjac100. Epub ahead of print.
197. Bezzio C, Fiorino G, Ribaldone DG, Armuzzi A, Saibeni S; IG-IBD COVID-19 Study Group. IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame. *Inflamm Bowel Dis*. 2022 Aug 16;izac173. doi: 10.1093/ibd/izac173. Epub ahead of print.
198. Caviglia GP, Nicolosi A, Abate ML, Carucci P, Rosso C, Rolle E, Armandi A, Aneli S, Olivero A, Risso A, Ribaldone DG, Fermer C, Saracco GM, Gaia S, Bugianesi E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. *Curr Oncol*. 2022 Jul 31;29(8):5457-5465. doi: 10.3390/curroncol29080431. PMID: 36005169; PMCID: PMC9406939.
199. Caviglia GP, Mineo CA, Rosso C, Armandi A, Astegiano M, Canavese G, Resegotti A, Saracco GM, Ribaldone DG. Predictive Factors of Surgical Recurrence in Patients with Crohn's Disease on Long-Term Follow-Up: A Focus on Histology. *J Clin Med*. 2022 Aug 27;11(17):5043.
200. Daneshvar M, Yadegari A, Ribaldone DG, Hasanzadeh M, Djafarian K. Zonulin levels in complicated pregnancy: a systematic review and meta-analysis. *J Obstet Gynaecol*. 2022 Sep 12;1-8. doi: 10.1080/01443615.2022.2114822. Epub ahead of print. PMID: 36094006.
201. Baima G, Muwalla M, Testa G, Mazza F, Bebars A, Perotto S, Venero M, Massano A, Romano F, Ribaldone DG, Aimetti M. Periodontitis Prevalence and Severity in Inflammatory Bowel Disease: A Case-Control Study. *J Periodontol*. 2022 Sep 16. doi: 10.1002/JPER.22-0322.
202. Macaluso FS et al. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study. *Dig Liver Dis*. 2022 Aug 29;S1590-8658(22)00656-9. doi: 10.1016/j.dld.2022.08.027. Epub ahead of print.
203. Nicolosi A, Gaia S, Risso A, Rosso C, Rolle E, Abate ML, Olivero A, Armandi A, Ribaldone DG, Carucci P, Fagoonee S, Pellicano R, Saracco GM, Bugianesi E, Caviglia GP. Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma. *Minerva Gastroenterol (Torino)*. 2022 Oct 12. doi: 10.23736/S2724-5985.21.03006-0. Epub ahead of print.
204. Fornaro R, Actis GC, Caviglia GP, Pitoni D, Ribaldone DG. Inflammatory Bowel Disease: Role of Vagus Nerve Stimulation. *J Clin Med*. 2022 Sep 26;11(19):5690. doi: 10.3390/jcm11195690.
205. Rosso C, Demelas C, Agostini G, Abate ML, Venero M, Caviglia GP, D'Amato D, Armandi A, Tapparo M, Guariglia M, Troshina G, Massano A, Olivero A, Nicolosi A, Zannetti A, Pellicano R, Ciancio A, Saracco GM, Ribaldone DG, Bugianesi E, Fagoonee S. Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis. *Viruses*. 2022 Oct 29;14(11):2397.

National Scientific Qualification for Associate Professor - sector 06/D4 (SKIN DISEASES, INFECTIOUS DISEASES AND DISEASES OF THE DIGESTIVE SYSTEM) (from 10 JUL 2020)

Abstracts: 68

Other publications: 8

Editorial board of Journals on Pubmed: 1

Guest Editor for special issues: 3

Reviewer for different Journals on Pubmed: 94

Scientific Director, Scientific Committee or Scientific Secretary for national or international congresses: 11

Teacher in different editions of masters: 1

Lecturer in the Specific Training Course in General Medicine

Scientific meetings attended as speaker or tutor: 38

For a full list of publications: <http://www.linkedin.com/pub/davide-giuseppe-ribaldone/39/339/792>

Winner of calls for research projects: 4

Awards:

- VII Giuseppe d'Albasio Award (best oral communication XI IG-IBD congress 2020)
- Best contribution of the poster session (28th National Congress of Digestive Diseases 2022)

Member of professional associations:

IG-IBD - Italian Group for Inflammatory Bowel Diseases (from 2015; from 2018 member of the IG-IBD Scientific Board)

AGGEI - Associazione Giovani Gastroenterologi ed Endoscopisti Italiani (from 2011)

SIGR - Società Italiana di GastroReumatologia (from 2014)

ECCO - European Crohn's and Colitis Organisation

COLMAD (COLlegio unico dei docenti delle Malattie dell'Apparato Digerente) – UNIGASTRO

(Coordinamento Nazionale dei Docenti di Gastroenterologia) (from 2020) (from 2020 to 2024 councilor of the COLMAD council)

SIGE - Società italiana di Gastroenterologia ed Endoscopia digestiva (from 2020)

Last update December 2022

In compliance with the GDPR (UE 2016/679) and Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance with art. 7 of the above-mentioned Decree.

Signature Davide Giuseppe Ribaldone
